VALN
Valneva
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
VALN Profile
Valneva Se
An innovative biotech company that develops prophylactic vaccines for deadly and infectious diseases
Biological Technology
03/24/1999
05/06/2021
NASDAQ Stock Exchange
713
12-31
Depository Receipts (Ordinary Shares)
6 rue Alain Bombard, 44800 Saint-Herblain, France
--
Valneva SE was incorporated in France on March 24, 1999. The company is a specialty vaccine company focused on the development, manufacture and commercialization of preventive vaccines for infectious diseases. The company takes a highly specialized and targeted approach to vaccine research and development, focusing on vaccine solutions that address unmet needs to ensure that people's lives are transformed. The company uses a deep understanding of vaccine science, including expertise in multiple vaccine models, and established vaccine development capabilities to develop vaccines for diseases that are not yet preventable by vaccines or have limited effective treatment options. The company's current clinical portfolio consists of a number of highly differentiated vaccine candidates designed to provide preventive solutions for diseases with high unmet needs. VLA 1553 for chikungunya virus is the first and only chikungunya vaccine candidate to report positive Phase 3 top-line data and the first candidate to submit a biological product license application to the U.S. Food and Drug Administration.